Vimta Labs Limited

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming no dematerialization of shares during the quarter ended 30th September 2026.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Trading Window for transactions in shares of the Company will remain closed from 01 October 2026 till 48 hours post declaration of unaudited financial results for the quarter and half year ended 30 September 2026.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange regarding allotment of 12,955 securities pursuant to ESOP/ESPS at its meeting held on September 16, 2026, increasing the paid-up share capital from 8,93,73,808 to 8,93,99,718.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange about the schedule of an analyst/institutional investor meet.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange about Credit Rating reaffirmation by CARE Ratings Limited for its bank facilities.

Vimta Labs Limited

Vimta Labs Limited has responded to a query from the National Stock Exchange regarding a significant increase in trading volume in the company's shares, stating that all necessary disclosures have been made in a timely manner and that the price movement is due to market factors.

Vimta Labs Limited

Vimta Labs Limited has seen a significant increase in volume, prompting the exchange to write to the company for a response.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange about the schedule of meetings with investment analysts, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meetings are scheduled to understand the company's business operations and will be held on September 4 and 9, 2026.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange about the schedule of meetings with investment analysts, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meetings are scheduled to understand the company's business operations and will be held on September 4 and 9, 2026.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange regarding a cyber security incident affecting a part of its IT infrastructure. The company has initiated containment measures and engaged external cybersecurity experts to assess and support remediation. Operations and customer delivery services have remained fully functional.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange about the schedule of meetings with investment analysts to understand the company's business operations.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange about the schedule of meetings with investment analysts to understand the company's business operations.

Vimta Labs Limited

Vimta Labs Limited has announced its Q1 FY '27 earnings, with total income standing at INR1,129 million, representing a 13.7% year-on-year growth. The company's pharma contact research and testing services delivered a consistent performance, while clinical research operations showed encouraging signs of recovery. The environment division has been integrated with the food division for more efficient management and operational alignment.

Vimta Labs Limited

Vimta Labs Limited informed the National Stock Exchange (NSE) that it has submitted a copy of a newspaper publication as part of its regulatory disclosure obligations. The filing does not contain any financial, operational or strategic details; it is a procedural compliance submission. No impact on the company's earnings, growth prospects or balance sheet is implied by this announcement.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange about the link of the recording of the Q1 FY 2026-27 Earnings/Investor Call held on July 20, 2026, available on the company's website.

Vimta Labs Limited

Vimta Labs Limited has announced its Q1 FY27 results, with a total income of ₹1,129 Mn, up 13.7% YoY. EBITDA margins were at 36.4% and PAT margin was at 18.6%. The company has also commenced operations in Biologics contract research and development services (CRADS).

Vimta Labs Limited

Vimta Labs Limited has released its Q1 FY27 investor presentation, highlighting its Q1 FY27 earnings, company overview, and future growth prospects.

Vimta Labs Limited

Vimta Labs Limited has submitted its financial results for the period ended June 30, 2026.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange about the schedule of an Analyst/Investor Conference Call to be held on Monday, 20th July 2026 at 4:00 P.M. (IST) following the announcement of the unaudited Financial Results for the quarter ended 30th June 2026 for the Financial Year 2026-27.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance with Regulation 74(5) for the quarter ended June 2026.